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Edited by Ned ManteiAbstract Peptidylarginine deiminase IV (PAD IV) catalyzes
the citrullination of Arg residues of proteins, such as histones.
Suzuki et al. recently reported that haplotypes of the PAD IV
gene are associated with susceptibility to rheumatoid arthritis.
To investigate the mechanism of substrate speciﬁcity and inhib-
itors of PAD IV, a series of the Arg derivatives were synthesized
and their reactivity to PAD IV examined. The results suggest
that both imino and carboxyl groups are important in the molec-
ular recognition of PAD IV and that methylation of the guani-
dino group prevents citrullination. In addition, the ﬁndings
herein show that Bz-NG-monomethyl-Arg and Bz-NG,NG-di-
methyl-Arg speciﬁcally inhibit citrullination.
 2005 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
Keywords: Peptidylarginine deiminase; Histone; Citrullination;
Methylation; Inhibitor1. Introduction
Peptidylarginine deiminase IV (PAD IV), which is mainly
found in bloodstream granulocytes, catalyzes the deimination
of the guanidino group of Arg residues of various peptides
and proteins, such as nucleophosmin/B23 and histones, result-
ing in the production of citrulline residues in granulocytes
[1–3]. The expression of the PAD IV gene is closely associated
with granulocyte diﬀerentiation [4]. Suzuki et al. [5] reported
that haplotypes of the PAD IV gene were associated with a
susceptibility to rheumatoid arthritis, and implied that the
rheumatoid arthritis is associated with higher levels of an
antibody to citrullinated proteins in sera. However, the precise
relationship between rheumatoid arthritis and PAD IV has not
been fully explained.
The PAD family consists of ﬁve types of PAD proteins [6].
Among these, only PAD IV is localized in the cell nucleusAbbreviations: TFA, triﬂuoroacetic acid; RP-HPLC, reversed phase
high performance liquid chromatography; Tris/HCl, tris(hydroxy-
methyl)aminomethane hydrochloride; DMF, dimethyl formamide;
AcOEt, ethyl acetate; MALDI-TOFMS, matrix-assisted laser desorp-
tion/ionization time of ﬂight mass spectrometry; DTT, dithiothreitol;
ADMA, NG,NG-dimethyl-L-arginine (asymmetric form); SDMA,
NG,N0G-dimethyl-L-arginine(symmetric form)
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that it contains ﬁve Ca2+-binding sites and a classical mono-
partite nuclear localization signal in the N-terminal domain
[7]. Core histones have recently been identiﬁed as target cellu-
lar proteins of PAD IV. The N-terminal tails of histones H3
and H4 have been shown to be citrullinated by PAD IV and
it has been shown that the citrullination of these histones
antagonizes the methylation of Arg residues by CARM1 and
PRMT1, resulting in the regulation of gene transcription
[8,9]. More importantly, it has been shown that PAD IV cata-
lyzes the citrullination of, not only Arg residues but also the
NG-monomethyl-Arg residue in histone [8,9]. PAD IV appears
to speciﬁcally regulate histone Arg methylation by converting
NG-methyl-Arg to citrulline, resulting in the transcriptional
regulation of estrogen-responsive genes. In fact, it has been
demonstrated that the transcriptional activation of the pS2
promoter in MCF-7 cells by estrogen is suppressed by the
PAD IV-dependent citrullination of histones H3 and H4 [8,9].
In this paper, we report on the results of a study of speciﬁc
inhibitors and the molecular recognition of PAD IV, in
attempt to better understand the role of PAD IV in gene
expression. The issue of whether PAD IV catalyzes the citrul-
lination of a series of the NG-methylated-Arg derivatives was
explored in vitro. The results clearly indicate that the methyl-
ation of the imino group of an Arg residue dramatically
decreases the extent of its citrullination by PAD IV. In
addition, we found that both benzoyl-NG-monomethyl-Arg
and benzoyl-NG,NG-dimethyl-Arg (Bz-ADMA) speciﬁcally
inhibit the enzyme activity of PAD IV.2. Materials and methods
2.1. Materials
NG-monomethyl-L-arginine was purchased from Wako Pure
Chemical Industries (Osaka, Japan). NG,NG-dimethyl-L-arginine
(ADMA: asymmetric form) and NG,N 0G-dimethyl-L-arginine (SDMA:
symmetric form) were purchased from ALEXIS Biochemicals (Lausen,
Switzerland). H2
18O (95%) was purchased from Cambridge Isotope
Laboratories, Inc. All other chemicals and solvents were of reagent
grade.
2.2. Syntheses of Bz-Arg derivatives
The Arg (10 lmol) derivative in 0.1 M NaHCO3 (200 ll) was mixed
with Bz2O (10 lmol) in dimethyl formamide (DMF) (200 ll) at room
temperature and allowed to stand for 1 h. After the addition of
200 ll of water, the reaction solution was washed three times with
AcOEt. The solution was acidiﬁed by the addition of 100 ll of 1 M
HCl and washed four times with AcOEt. The desired product wasation of European Biochemical Societies.
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(RP-HPLC), as described below. Bz-Arg derivatives were determined
by matrix-assisted laser desorption/ionization time of ﬂight mass spec-
trometry (MALDI-TOFMS) and amino acid analysis, as previously
described [10].2.3. Synthesis of the N-terminal peptide of histoneH4
The H4-10 peptide (Ac-SGRGKGGKGL) was chemically synthe-
sized by the solid phase method [11]. An N-terminal acetyl group
was introduced using acetic anhydride. All protecting groups and the
resin were removed by treatment with anhydrous HF, and the resulting
peptide was extracted with 10% acetic acid, as previously reported
[10,12]. The synthetic peptide was puriﬁed by RP-HPLC and charac-
terized by MALDI-TOFMS and amino acid analysis [10].2.4. Assay of PAD IV activity
Homogenously puriﬁed recombinant PAD IV was the same as that
described previously [3] and its activity was determined under the same
conditions as described previously [18]. The Bz-Arg derivatives were
treated with PAD IV, as previously described [18]. The reaction was
conducted in the presence of dithiothreitol (DTT), since the catalytic
residue of PAD is a Cys residue [7]. Brieﬂy, the Bz-Arg derivative
(5 nmol) in 0.1 M tris(hydroxymethyl)aminomethane hydrochloride
(Tris/HCl) buﬀer (50 ll, pH 7.6) containing 1 mM DTT and 10 mM
CaCl2 was incubated with PAD IV (0.02 unit) at 37 C for several
hours, typically 4 h. The reaction was quenched by the addition of
0.1 M HCl (50 ll) and the products were analyzed by RP-HPLC and
mass spectrometry.
2.5. Inhibition assay of the methylated-Arg derivatives
Bz-Arg was treated with PAD IV in the presence or absence of
benzoyl methylated-Arg derivatives. Brieﬂy, Bz-Arg (5 nmol) in
0.1 M Tris/HCl buﬀer (50 ll, pH 7.6) containing 1 mM DTT and
10 mM CaCl2 was incubated with PAD IV (0.02 unit) in the presence
of Bz-methylated-Arg derivative (20 nmol) at 37 C for 40 or 60 min.
The reaction was quenched by the addition of 0.1 M HCl (50 ll) and
the products were analyzed by RP-HPLC and MALDI-TOFMS.
To estimate the IC50 value of Bz-ADMA, an inhibition assay was
performed in the presence of several concentrations (1 lM to
10 mM) of Bz-ADMA under the same conditions as above [13]. The
amounts of Bz-citrulline were quantiﬁed by HPLC and the IC50 value
of Bz-ADMA was estimated by the curve ﬁtting method.
2.6. Citrullination of the H4-10 peptide in the presence of H2
18O
The H4-10 peptide (5 nmol) in 0.1 M Tris/HCl (50 ll, pH 7.6) con-
taining 10 mM CaCl2 was lyophylized and the residue was then re-
dissolved in 10 ll of H2
18O (95%), and lyophylized again. The resulting
residue was dissolved in 50 ll of H2
18O and mixed with 0.1 M DTT
(0.5 ll) and PAD IV (0.02 unit/0.2 ll) at 37 C for 60 min under a
N2 atmosphere. The reaction was quenched by the addition of 0.1 M
HCl (50 ll) and the products were analyzed by RP-HPLC and mass
spectrometry. All procedures were carried out under an atmosphere
of N2.
2.7. Reversed phase high performance liquid chromatography
The HPLC apparatus was comprised of a Waters M600 multisolvent
delivery system (Bedford, MA) equipped with a Hitachi L-3000 photo-
diode array detector and a D-2000 chromato-integrator (Tokyo,
Japan), as previously described [10]. The Arg derivatives were analyzed
by RP-HPLC using ODS columns. The compounds were eluted using
a linear gradient of CH3CN in 0.05% triﬂuoroacetic acid (TFA) at a
rate of 1%/min from 5% CH3CN at a ﬂow rate of 1 ml/min. To eﬃ-
ciently separate the citrulline- and Arg-containing peptides, Develosil
C30 UG-3 (Nomura Chemicals, Aichi) and Hydrosphere C18
(Yamamura Chemical, Kyoto) columns were employed.
2.8. Mass spectrometric analysis
MALDI-TOFMS was carried out using a Voyagere RP DE instru-
ment (Applied Biosystems). The spectra were measured at the reﬂector
mode in the positive ion mode using a-cyano-4-hydroxycinnamic acid
as the matrix.3. Results and discussion
3.1. Substrate speciﬁcity of PAD IV
PAD family, which catalyzes the citrullination of Arg resi-
dues in proteins, consists of ﬁve types of human PAD, PAD
I-IV and PAD VI. The carboxyl terminal-proximal two thirds
of their sequences, containing substrate binding and catalytic
sites, are highly similar [4,7,14–17]. It has been shown that
PAD IV citrullinates the NG-monomethyl-Arg residue in
histone H3 and H4, as evidenced by a sequence analysis using
a radio isotope and Western blotting using the anti-NG-
monomethyl-Arg antibody [8,9]. Both symmetric and asym-
metric dimethyl arginines in the H3 N-terminal peptides are
not targeted [8]. The dimethylation of arginine in the H3 and
H4 N-terminal tails appears to be involved in the transcrip-
tional activation of estrogen-regulated genes [8,9]. Therefore,
the synthesis of some speciﬁc inhibitors of PAD IV was carried
out to further investigate the role of PAD IV in cells. For this
purpose, we chemically synthesized a series of Bz-Arg deriva-
tives, in which the guanidino group was methylated, and
examined the citrullination reaction catalyzed by PAD IV in
order to elucidate its substrate speciﬁcity.
The Arg derivatives were treated with benzoic anhydride in
0.1 M NaHCO3 solution, to prepare the Bz-Arg derivatives
since the a-amino group of an Arg residue must be modiﬁed
with a carbonyl group in the citrullination reaction catalyzed
by PAD IV [7,19]. The a-amino group of the Arg derivatives
is selectively protected by the benzoyl group under these
conditions. Bz-Arg was citrullinated by PAD IV in a yield of
approximately 25–30% after a 40 min reaction under the
condition used in this experiment, based on HPLC analysis,
as shown in Fig. 1A. However, Bz-NG-monomethyl-Arg,
Bz-NG,NG-dimethyl-arginine (Bz-ADMA), and Bz-NG,N 0G-di-
methyl-arginine (Bz-SDMA) were not citrullinated by PAD
IV. Even after 4 h, a suﬃcient time for the complete conversion
of Bz-Arg to Bz-citrulline by PAD IV, no citrullination of
Bz-NG-monomethyl-Arg, Bz-ADMA, and Bz-SDMA was
detected, as shown in Fig. 1B and D. MALDI-TOFMS analy-
ses of reaction mixtures of Bz-NG-monomethyl-Arg,
Bz-ADMA, and Bz-SDMA also strongly indicated that the
methylation of the guanidino group of Arg dramatically
decreased the eﬃciency of citrullination by PAD IV(data not
shown). To conﬁrm that no Bz-NG-monomethyl-Arg deriva-
tive is citrullinated by PAD IV, Bz-Gly-NG-monomethyl-Arg
was also treated with PAD IV. In this reaction, no citrullinated
product was observed by HPLC or mass spectrometric analysis
(data not shown). Therefore, we conclude that the methylation
of the guanidino group of the Arg residue has a dramatic eﬀect
in preventing citrullination by PAD IV.
The complete absence of citrullination of Bz-ADMA and
Bz-SDMA on incubation with PAD IV is consistent with the
previous ﬁnding that asymmetric and symmetric dimethyl
arginines in the H3 N-terminal peptides with 5–13 amino acid
in length are not citrullinated, although the corresponding
arginine peptides are eﬃciently citrullinated [8]. Diﬀering from
Bz-NG-monomethyl-Arg, NG-monomethyl-arginine residues
in histone H3 and H4 are susceptible to the action of PAD
IV, especially in parallel concomitance with the release of
methyl arginine in H4 [8,9]. However, the H4 N-terminal
methyl-arginine peptide, consisting of 16 amino acid residues,
was not susceptible to the enzyme action, similar to
Bz-NG-monomethyl-Arg in our experiments [9]. It is known
Fig. 2. HPLC analyses of the inhibition assay in the citrullination of
PAD IV. Bz-Arg was treated with PAD IV for 40 min in the absence
(A) and presence of Bz-NG-monomethyl-Arg (B), Bz-ADMA (C),
Bz-SDMA (D). In the HPLC proﬁles, a, b, c, d and e indicate
the positions of Bz-Arg, Bz-citrulline, Bz-NG-monomethyl-Arg,
Bz-ADMA, and Bz-SDMA, respectively.
Fig. 1. HPLC proﬁles of citrullination reactions of the Bz-Arg
derivatives. (A) Bz-Arg, (B) Bz-NG-monomethyl-Arg, (C) Bz-ADMA,
(D) Bz-SDMA. Bz-Arg and the other Bz-methylated-Arg derivatives
were treated with PAD IV for 40 min and 4 h, respectively. DTTred and
DTTox represent the reduced and oxidized forms of DTT, respectively.
The chemical structures of the guanidino group of Bz-NG-mono-
methyl-Arg, Bz-ADMA, and Bz-SDMA were superimposed in (B–D),
respectively.
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sometimes adopts conformations that are diﬀerent from the
conformation in the original protein. Therefore, the diﬀerence
in the substrate recognition of PAD IV might be caused by
conformational diversity. Similarly, NG-monomethyl-arginine
at position 3 in H4 is susceptible, when incubated with PAD
II, but Bz-NG-monomethyl-Arg-OEt is not [20,21]. Concern-
ing the substrate peptide length, three to four amino acid
residues preceding the Arg residue appears to be essential
and suﬃcient for the eﬀective catalytic action of PAD IV
[21]. Collectively, these results suggest that NG-monomethyl-
arginine citrullination in H4 and H3 appears to proceed with
a much lower eﬃciency than arginine citrullination.
To further estimate the substrate speciﬁcity of PAD IV,
Bz-agmatine was prepared and used as a substrate in the citrul-
lination reaction. No citrullination was observed, as evidenced
by HPLC and mass spectrometric analyses (data not shown),
indicating that both the length of the side chain and the
carbonyl group of the Arg residue are important for the
substrate recognition of PAD IV. Taken together, we conclude
that PAD IV speciﬁcally recognizes the Arg structure in the
citrullination.
3.2. Inhibition abilities of the Bz-Arg derivatives
To determine whether theNG-methylated Arg derivatives are
able to bind to PAD IV and to explore speciﬁc inhibitors, the
inhibition activities of Bz-NG-monomethyl-Arg, Bz-ADMA,and Bz-SDMA were examined for the citrullination of Arg by
PAD IV. For this purpose, Bz-Arg was treated with PAD IV
in the presence and absence of the NG-methylated Arg deriva-
tive. Fig. 2 shows HPLC proﬁles of the reaction mixture for the
inhibition assay. The yields of Bz-citrulline were markedly
decreased in the presence of Bz-NG-monomethyl-Arg or
Bz-ADMA, as shown in Fig. 2B and C. However, Bz-SDMA
did not show any inhibition under the conditions employed.
The inhibition activities are summarized in Fig. 3A. These
results indicate that PAD IV is able to bind Bz-NG-monom-
ethyl-Arg and Bz-ADMA, but is not able to citrullinate the
Bz-NG-methylated Arg derivatives. These results suggest that
the modiﬁcation at the guanidino group by a methyl group
might interrupt the attack on the carbon in the guanidino group
by the active thiol group of PAD IV in the mechanism of
citrullination via steric hindrance [7].
To further estimate the inhibition ability, the IC50 value of
Bz-ADMA, which showed the highest inhibition activity
among the Arg derivatives tested, was determined. Bz-Arg
was treated with PAD IV in the presence of various concentra-
tions of Bz-ADMA. Citrullination was inhibited in a concen-
tration dependent manner, as shown in Fig. 3B. The IC50
value of Bz-ADMA was estimated to be 400 lM under the
conditions used (against 100 lM Bz-Arg). This value is nearly
half that of the Km value of Bz-Arg with 0.9 mM for PAD IV
(4). Thus, the inhibition ability of Bz-ADMA is a quite
modest.
Fig. 4. The citrullination of the H4-10 peptide by PAD IV in
18O-labeled H2O (H2
18O). (A) H4-10 peptide was synthesized by the
solid phase method, treated with anhydrous HF, and puriﬁed by
HPLC. (B) H4-10 was treated with PAD IV in Tris/HCl buﬀer (pH 7.6)
in the presence of H2
18O. A YMC hydrosphere column was used to
separate the peptides by HPLC. The symbols, a and b, represent the
H4-10 peptide and the citrullinated H4-10 peptide, respectively.
Fig. 5. MALDI TOF mass spectrometric analyses of the citrullination
of the H4-10 peptide by PAD IV in the presence or absence of H2
18O.
(A) H4-10 peptide before treatment with PAD IV. (B) H4-10 peptide
after treatment with H2
18O without PAD IV. (C) H4-10 peptide after
treatment with PAD IV in H2
16O. (D) H4-10 peptide after treatment
with PAD IV in H2
18O and separated by HPLC, as shown in Fig. 4B.
Fig. 3. Inhibition activities of the Bz-methylated-Arg derivatives in the
citrullination of Bz-Arg by PAD IV. (A) Yields of Bz-citrulline in the
citrullination of Bz-Arg by PAD IV in the presence of Bz-SDMA (a),
Bz-ADMA (b), and Bz-NG-monomethyl-Arg (c), as shown in Fig. 2A.
The control experiment for the citrullination of Bz-Arg was performed
in the absence of the Bz-methylated Arg derivatives (d in Fig. 2A).
(B) Inhibition curve of Bz-ADMA in the citrullination of Bz-Arg.
The points were plotted as the average of duplicate experiments.
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PAD IV introduces an oxygen atom into an Arg residue in
place of the imino group in the catalytic reaction. In the
reaction mechanism, there are two possible sources of oxygen,
O2 and H2O molecules. Recently, Kubota et al. examined the
citrullination reaction by PAD IV in H2
18O to assign the citrul-
linated residue [22]. They observed the incorporation of 18O
into citrulline. However, the reaction was not carried out in
the absence of O2 molecules. To minimize the possibility of
exchange of the oxygen atoms between H2O and O2, we exam-
ined the citrullination of a peptide in the presence of H2
18O
under a N2 atmosphere to eliminate as much O2 as possible.
The Arg3 residue in histone H4 was recently reported to be a
target residue for PAD IV in cells [9,23]. We, therefore, pre-
pared the N-terminal histone H4 peptide, consisting of 10
amino acid residues (H4-10, Ac-SGRGKGGKGL), as a
model peptide to investigate the citrullination mechanism by
PAD IV. The H4-10 peptide was chemically synthesized and
puriﬁed by HPLC, as shown in Fig. 4A.
To eliminate as much H2
16O as possible, the H4-10 peptide
in Tris/HCl buﬀer was lyophilized and pre-treated with
H2
18O, as described in Section 2. The H4-10 peptide was trea-
ted with H2
18O in the absence of PAD IV and analyzed by
MALDI-TOFMS after puriﬁcation by HPLC. The non-
speciﬁc exchange reaction was not signiﬁcant, as shown in
Fig. 5A and B. We also examined the reaction of PAD IV
in the presence of H2
16O. The mass value of the H4-10
peptide ð½MþHþobs ¼ 958.7; ½MþHþcalc ¼ 958.5Þ was shifted
to 959.7 (Fig. 5A and C), indicating that Arg3 in the H4-10
peptide was citrullinated by PAD IV because citrullination
increases the molecular weight of the H4-10 peptide by one
mass unit in the reaction. Therefore, we treated the H4-10
peptide with PAD IV in the presence of H2
18O and the reaction
product was puriﬁed by HPLC, as shown in Fig. 4B, and ana-
lyzed by mass spectrometry. The molecular ion of the citrul-
linated H4-10 peptide ð½MþHþobs ¼ 961.8; ½MþHþcalc ¼ 961.5Þ
appeared at a position three and two mass units higher than
those of the H4-10 and the H4-10 peptides citrullinated in
H2
16O, respectively, as shown in Fig. 5D, indicating that
the oxygen atom (18O) of H2
18O was introduced into the
citrulline residue. These data clearly show that the reaction
proceeds hydrolytically.In this study, we provide evidence as to which Bz-NG-
monomethyl-Arg and Bz-ADMA inhibits the citrullination
of an Arg residue by PAD IV. Further studies of whether these
substrate analogues inhibit the cellular enzyme in vivo are
currently in progress in our laboratory. The dimethylation of
Arg residues in histone H3 by CARM1 and that of H4 by
PRMT1 are linked to the activation of estrogen-regulated
genes [8,9]. Citrullination is also thought to antagonize tran-
scriptional activation mediated by Arg methylation. Therefore,
one can speculate that the NG-methylated-Arg residues in
histone cooperatively inhibit the citrullination of other Arg
residues of histones by PAD IV, resulting in an enhancement
in transcriptional activation. The results presented here
4092 Y. Hidaka et al. / FEBS Letters 579 (2005) 4088–4092provide a clue for studying the mechanism of the gene regula-
tion in transcription by the histones, PRMT1, and CARM1.
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